Related Experiment Video

Updated: Jan 24, 2026

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

6.3K

New Therapies for Ovarian Cancer

David M O'Malley

    Journal of the National Comprehensive Cancer Network : JNCCN
    |May 23, 2019
    PubMed

    Insights

    New ovarian cancer treatments offer improved survival. Three PARP inhibitors (olaparib, rucaparib, niraparib) and extended bevacizumab indications provide new options for maintenance and recurrent disease management.

    Area of Science:

    • Oncology
    • Gynecologic Oncology
    • Pharmacology

    Background:

    • Ovarian cancer treatment has seen limited progress for decades.
    • Recent advancements offer new therapeutic strategies.
    • Improved patient survival is a key objective.

    Purpose of the Study:

    • To review recent advancements in ovarian cancer treatment.
    • To highlight new therapeutic options and their indications.
    • To discuss the impact of novel agents on patient survival.

    Main Methods:

    • Review of recent clinical trials and approvals.
    • Analysis of new drug indications for ovarian cancer.
    • Comparison of survival outcomes with historical data.

    Main Results:

    • Three new Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib, rucaparib, niraparib) are now available.
    • Bevacizumab indications have been expanded.
    • Combination chemotherapy regimens with bevacizumab are established for initial and maintenance therapy.

    Conclusions:

    • Novel therapeutic agents are significantly improving ovarian cancer treatment.
    • PARP inhibitors and bevacizumab offer new avenues for managing recurrent and refractory disease.
    • These advancements provide hope for longer survival in ovarian cancer patients.

    More Related Videos

    An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

    An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

    Published on: November 28, 2010

    18.8K
    In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

    In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

    Published on: February 18, 2015

    14.2K

    Related Concept Videos

    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    9.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.7K
    Ovarian Cycle01:27

    Ovarian Cycle

    The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
    3.6K
    Gene Therapy00:59

    Gene Therapy

    Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
    27.4K
    Group Therapy01:26

    Group Therapy

    Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
    391
    Hormonal Control of the Ovarian Cycle01:30

    Hormonal Control of the Ovarian Cycle

    The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
    Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
    6.5K